MX379043B - Uso de sobetirome en el tratamiento de enfermedades de mielinización. - Google Patents
Uso de sobetirome en el tratamiento de enfermedades de mielinización.Info
- Publication number
- MX379043B MX379043B MX2015015228A MX2015015228A MX379043B MX 379043 B MX379043 B MX 379043B MX 2015015228 A MX2015015228 A MX 2015015228A MX 2015015228 A MX2015015228 A MX 2015015228A MX 379043 B MX379043 B MX 379043B
- Authority
- MX
- Mexico
- Prior art keywords
- sobetirome
- myelinization
- diseases
- treatment
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819467P | 2013-05-03 | 2013-05-03 | |
| PCT/US2013/053640 WO2014178892A1 (en) | 2013-05-03 | 2013-08-05 | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PCT/US2014/014943 WO2014178931A1 (en) | 2013-05-03 | 2014-02-05 | Sobetirome in the treatment of myelination diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015015228A MX2015015228A (es) | 2016-10-03 |
| MX379043B true MX379043B (es) | 2025-03-10 |
Family
ID=51843844
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015228A MX379043B (es) | 2013-05-03 | 2014-02-05 | Uso de sobetirome en el tratamiento de enfermedades de mielinización. |
| MX2021000538A MX2021000538A (es) | 2013-05-03 | 2015-10-30 | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000538A MX2021000538A (es) | 2013-05-03 | 2015-10-30 | Uso de sobetirome en el tratamiento de enfermedades de mielinizacion. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10226438B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2991670B8 (cg-RX-API-DMAC7.html) |
| JP (4) | JP2016517883A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105431163A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014260468A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015027682A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2911309A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2745532T3 (cg-RX-API-DMAC7.html) |
| MX (2) | MX379043B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015151216A (cg-RX-API-DMAC7.html) |
| SG (2) | SG10201709090UA (cg-RX-API-DMAC7.html) |
| WO (2) | WO2014178892A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| AU2015253100B2 (en) | 2014-04-30 | 2018-01-18 | The Johns Hopkins University | Dendrimer compositions and their use in treatment of diseases of the eye |
| CN115350285A (zh) | 2014-08-13 | 2022-11-18 | 约翰霍普金斯大学 | 树枝状聚合物到脑肿瘤的选择性传递 |
| US20170119899A1 (en) * | 2015-10-29 | 2017-05-04 | The Johns Hopkins University | Compositions and methods for treatment of peroxisomal disorders and leukodystrophies |
| EP3445372A4 (en) * | 2016-04-22 | 2020-03-25 | Viking Therapeutics, Inc. | USE OF THYROID BETA AGONISTS |
| EP3445373B1 (en) | 2016-04-22 | 2024-08-21 | Viking Therapeutics, Inc. | Use of thyroid beta-agonists |
| LT3457851T (lt) | 2016-05-18 | 2021-10-11 | Oregon Health & Science University | Sobetiromo dariniai |
| AU2017310535B2 (en) * | 2016-08-12 | 2021-11-11 | Oregon Health & Science University | Amide compounds, pharmaceutical compositions thereof, and methods of using the same |
| WO2018183940A1 (en) * | 2017-03-31 | 2018-10-04 | Neurovia, Inc. | Methods and compositions for treating niemann-pick disease |
| IL270169B2 (en) | 2017-04-27 | 2024-08-01 | Univ Johns Hopkins | Dendrimer preparations for use in angiography |
| WO2018208707A1 (en) * | 2017-05-08 | 2018-11-15 | Neurovia, Inc. | Methods and compositions for treating demyelinating diseases |
| US10780069B2 (en) * | 2017-05-18 | 2020-09-22 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of GC-1 in transplant related population |
| US11660281B2 (en) | 2017-06-29 | 2023-05-30 | Yale University | Compositions and methods of treating or preventing fibrotic lung diseases |
| US11633433B2 (en) * | 2017-07-18 | 2023-04-25 | Keio University | Anti-bacterial composition against TH1 cell-inducing bacteria |
| CN111615528A (zh) | 2017-11-10 | 2020-09-01 | 约翰霍普金斯大学 | 树枝状聚合物递送系统和其使用方法 |
| CN113423684A (zh) | 2018-12-12 | 2021-09-21 | 速通医疗公司 | 新型拟甲状腺素药 |
| US11667606B2 (en) | 2019-03-01 | 2023-06-06 | Autobahn Therapeutics, Inc. | Thyromimetics |
| MX2022006470A (es) | 2019-11-29 | 2022-08-04 | Autobahn Therapeutics Inc | Tiromimeticos novedosos. |
| WO2021113662A2 (en) | 2019-12-04 | 2021-06-10 | Ashvattha Therapeutics, Inc. | Dendrimer compositions and methods for drug delivery to the eye |
| CN111116684B (zh) * | 2019-12-31 | 2020-09-25 | 厦门甘宝利生物医药有限公司 | 一种具有甲状腺激素受体激动剂特性的肝靶向化合物及其药物组合物 |
| CN115569233B (zh) * | 2022-10-17 | 2023-07-14 | 湖南大学 | 既能吸光又能与自由基反应的高效光抑制剂的制备方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3815221C2 (de) | 1988-05-04 | 1995-06-29 | Gradinger F Hermes Pharma | Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen |
| WO1997021993A2 (en) | 1995-12-13 | 1997-06-19 | The Regents Of The University Of California | Nuclear receptor ligands and ligand binding domains |
| EP1003530A4 (en) | 1996-08-20 | 2001-10-04 | Univ California | EYE TREATMENT USING SYNTHETIC THYROID HORMONE COMPOSITIONS |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
| KR20010053277A (ko) | 1998-06-30 | 2001-06-25 | 린다 에스. 스티븐슨 | 갑상선 호르몬 유사체 및 그 제조 방법 |
| US7560433B2 (en) | 2001-12-21 | 2009-07-14 | Biotempt B.V. | Treatment of multiple sclerosis (MS) |
| US7302347B2 (en) | 2002-12-10 | 2007-11-27 | The Regents Of The University Of California | Method for creating specific, high affinity nuclear receptor pharmaceuticals |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| CN1878545A (zh) * | 2003-09-15 | 2006-12-13 | 奥德威研究院 | 甲状腺激素类似物及其使用方法 |
| WO2006012015A2 (en) | 2004-06-29 | 2006-02-02 | Oregon Health And Science University | Methods and compositions for nerve regeneration |
| AU2005284879B2 (en) | 2004-09-15 | 2011-04-14 | Albany College Of Pharmacy And Health Sciences | Thyroid hormone analogs for promoting angiogenesis |
| WO2006105205A1 (en) | 2005-03-29 | 2006-10-05 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
| US8252329B2 (en) | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
| KR20090071652A (ko) * | 2006-10-20 | 2009-07-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료 |
| US8623861B2 (en) | 2006-11-03 | 2014-01-07 | Xin-Min Li | Method of treating demyelination diseases |
| FI20075245A0 (fi) * | 2007-04-11 | 2007-04-11 | Markku Ahotupa | Menetelmä oksidatiivisen metabolian arvioimiseksi |
| PL2187882T3 (pl) * | 2007-07-11 | 2013-05-31 | Medicinova Inc | Leczenie postępującej choroby neurodegeneracyjnej ibudilastem |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| KR20160029870A (ko) * | 2008-04-21 | 2016-03-15 | 오토노미, 인코포레이티드 | 귀 질환 및 병태를 치료하기 위한 귀 조제물 |
| EP2437730A4 (en) | 2009-05-20 | 2014-02-26 | Lingual Consegna Pty Ltd | ORAL AND / OR SUBLINGUAL THERAPEUTIC FORMULATION |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| AU2011343429B2 (en) | 2010-12-16 | 2016-10-20 | Sunovion Pharmaceuticals Inc. | Sublingual films |
| JP6060268B2 (ja) * | 2012-10-25 | 2017-01-11 | ボルボ トラック コーポレイション | 車両用電子制御エアブレーキシステム、そのようなシステムを備える車両及びそのようなシステムを制御する方法 |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
-
2013
- 2013-08-05 WO PCT/US2013/053640 patent/WO2014178892A1/en not_active Ceased
- 2013-08-05 JP JP2016511718A patent/JP2016517883A/ja not_active Withdrawn
-
2014
- 2014-02-05 CN CN201480038129.XA patent/CN105431163A/zh active Pending
- 2014-02-05 AU AU2014260468A patent/AU2014260468A1/en not_active Abandoned
- 2014-02-05 JP JP2016511726A patent/JP6360552B6/ja active Active
- 2014-02-05 SG SG10201709090UA patent/SG10201709090UA/en unknown
- 2014-02-05 BR BR112015027682A patent/BR112015027682A2/pt not_active IP Right Cessation
- 2014-02-05 CA CA2911309A patent/CA2911309A1/en not_active Abandoned
- 2014-02-05 US US14/888,577 patent/US10226438B2/en active Active
- 2014-02-05 EP EP14791718.1A patent/EP2991670B8/en active Active
- 2014-02-05 RU RU2015151216A patent/RU2015151216A/ru not_active Application Discontinuation
- 2014-02-05 ES ES14791718T patent/ES2745532T3/es active Active
- 2014-02-05 MX MX2015015228A patent/MX379043B/es unknown
- 2014-02-05 SG SG11201509012QA patent/SG11201509012QA/en unknown
- 2014-02-05 WO PCT/US2014/014943 patent/WO2014178931A1/en not_active Ceased
-
2015
- 2015-10-30 MX MX2021000538A patent/MX2021000538A/es unknown
-
2018
- 2018-06-22 JP JP2018118891A patent/JP2018141024A/ja active Pending
- 2018-07-23 JP JP2018137754A patent/JP2018162321A/ja active Pending
-
2019
- 2019-02-13 US US16/275,117 patent/US20190175531A1/en not_active Abandoned
-
2020
- 2020-07-07 US US16/922,852 patent/US11510887B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014178892A8 (en) | 2015-12-17 |
| EP2991670A1 (en) | 2016-03-09 |
| SG10201709090UA (en) | 2017-12-28 |
| JP6360552B2 (ja) | 2018-07-18 |
| WO2014178892A1 (en) | 2014-11-06 |
| WO2014178931A1 (en) | 2014-11-06 |
| US10226438B2 (en) | 2019-03-12 |
| JP6360552B6 (ja) | 2018-08-15 |
| US11510887B2 (en) | 2022-11-29 |
| WO2014178931A8 (en) | 2015-11-26 |
| EP2991670B1 (en) | 2019-07-03 |
| CA2911309A1 (en) | 2014-11-06 |
| US20200405669A1 (en) | 2020-12-31 |
| JP2018162321A (ja) | 2018-10-18 |
| MX2015015228A (es) | 2016-10-03 |
| RU2015151216A (ru) | 2017-06-08 |
| AU2014260468A1 (en) | 2015-11-19 |
| US20190175531A1 (en) | 2019-06-13 |
| BR112015027682A2 (pt) | 2017-08-29 |
| US20160081955A1 (en) | 2016-03-24 |
| HK1222552A1 (en) | 2017-07-07 |
| EP2991670A4 (en) | 2017-01-18 |
| JP2016517883A (ja) | 2016-06-20 |
| JP2018141024A (ja) | 2018-09-13 |
| CN105431163A (zh) | 2016-03-23 |
| EP2991670B8 (en) | 2019-09-11 |
| JP2016517884A (ja) | 2016-06-20 |
| ES2745532T3 (es) | 2020-03-02 |
| SG11201509012QA (en) | 2015-11-27 |
| MX2021000538A (es) | 2021-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX379043B (es) | Uso de sobetirome en el tratamiento de enfermedades de mielinización. | |
| MX2024004439A (es) | Agentes terapeuticos para enfermedades neurodegenerativas | |
| CY1125326T1 (el) | Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων. | |
| MX2017015226A (es) | Compuestos alqueno tetrasustituidos y su uso. | |
| LT3740504T (lt) | Cd70 kompleksinė terapija | |
| HUE056006T2 (hu) | Kombináció Parkinson-kór kezelésére | |
| PT3481846T (pt) | 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| MX385283B (es) | Tratamiento de cáncer usando 2-desoxi-2-fluoro-l-fucosa en combinación con un inhibidor del punto de control. | |
| MX380252B (es) | Crenezumab para usarse en el tratamiento de enfermedad de alzheimer. | |
| MA46621A (fr) | Traitements combinés comprenant l'administration d'imidazopyrazinones | |
| MX382776B (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| BR112017021583A2 (pt) | métodos para o tratamento de transtornos inflamatórios | |
| AR094241A1 (es) | Ciclesonida para el tratamiento de la enfermedad de las vias respiratorias en caballos | |
| HUE045148T2 (hu) | Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére | |
| TR201908151T4 (tr) | İzoindolin türevleri. | |
| BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
| HUE069280T2 (hu) | Ebselen a Meniere-kór kezelésére történõ felhasználásra | |
| CY1122418T1 (el) | Αγωγη ερυθρομελαλγιας | |
| IL258610B (en) | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer | |
| MX2017014540A (es) | Biomarcadores para una terapia combinada que comprende lenvatinib y everolimus. | |
| BR112017002449A2 (pt) | tratamento de sintomas associados com terapia de privação androgênica | |
| MX384394B (es) | Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas. | |
| BR112016028081A2 (pt) | Novos compostos como agentes antituberculares | |
| EA201692013A1 (ru) | Новое применение n,n-бис-2-меркаптоэтил-изофталамида |